InMed Pharmaceuticals

05/19/2026

InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies

"This transaction provides us with the capital and public market infrastructure to aggressively compete in what we believe will be the next era of migraine prevention. Recent anti-PACAP clinical studies have validated this novel mechanism and generated tremendous excitement among headache specialists. MT-001 and MT-002 were designed to be potentially best-in-class, with superior convenience through subcutaneous delivery and the potential for enhanced efficacy through rational dual pathway inhibition. We have a clear regulatory path, rapid development timelines benchmarked to approved migraine therapies, and are focused on bringing these potentially transformative therapies to the millions of people who continue to suffer despite current treatment options."

~ Julie Bruno, Chair of Mentari’s Board of Directors

Read news release: https://www.inmedpharma.com/news_release/inmed-pharmaceuticals-mentari-therapeutics-announce-merger-to-advance-migraine-prevention-therapies/

05/19/2026

InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies

-Mentari’s parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a suboptimal response to anti-CGRP therapies
-Concurrent oversubscribed US$290 million private placement of Mentari expected to fund company operations through 2028
-First-in-human regulatory filings for MT-001 (anti-PACAP) and MT-002 (anti-CGRP x PACAP bispecific) expected mid-2026 and 1Q 2027, respectively

Read news release: https://www.inmedpharma.com/news_release/inmed-pharmaceuticals-mentari-therapeutics-announce-merger-to-advance-migraine-prevention-therapies/

$INM

05/19/2026

InMed Pharmaceuticals & Mentari Therapeutics Announce Merger

"This merger with Mentari represents an excellent opportunity for InMed shareholders to participate in the development of an exciting new drug pipeline with significant therapeutic and commercial potential. InMed’s Board of Directors and management team are in full support of this transaction and believe that Mentari’s strong balance sheet positions the company to successfully execute on the development plans for its parallel lead programs in the treatment of migraines. We believe Mentari's lead programs have tremendous potential to expand and reshape the migraine treatment and prevention market.”

~ Eric A. Adams, President & CEO of InMed

Read full news release: https://www.inmedpharma.com/news_release/inmed-pharmaceuticals-mentari-therapeutics-announce-merger-to-advance-migraine-prevention-therapies/

$INM

05/19/2026

Today, InMed announced a definitive merger agreement with Mentari Therapeutics to advance a pipeline of potentially best-in-class therapies for migraine prevention. The transaction includes a concurrent oversubscribed private investment of US$290 million led by Fairmount with participation from Commodore Capital, Deep Track Capital, Janus Henderson Investors, a16z Bio + Health, Venrock Healthcare Capital Partners, Wellington Management, TCGX, Blackstone Multi-Asset Investing, BB Biotech, Farallon Capital, RTW Investments, LP, Vivo Capital, Perceptive Advisors and other leading investment management firms.

The combined company will focus on advancing MT-001, an anti-PACAP monoclonal antibody, and MT-002, an anti-CGRP x PACAP bispecific antibody, which are expected to drive the next wave of migraine prevention, given that 40-50% of those taking currently approved therapies do not achieve a 50% reduction in monthly migraine days, and fewer than one-third have a 75% reduction.

The merger and associated financing are expected to fund the company's efforts through 2028, positioning us to rapidly advance the co-lead programs through key clinical data inflection points, with regulatory submissions expected mid-2026 (MT-001) and 1Q 2027 (MT-002).

We are thrilled to celebrate this transformative milestone with all involved.

Read more: https://www.inmedpharma.com/news_release/inmed-pharmaceuticals-mentari-therapeutics-announce-merger-to-advance-migraine-prevention-therapies/

03/23/2026

InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer’s Disease Program. See full press release: https://ow.ly/6gR150Yxo1t

03/10/2026

InMed's President and CEO, Eric A. Adams, presents at Renmark Financial's Virtual Non-Deal Roadshow.

In the presentation and Q&A, Mr. Adams gives an overview of the company's pharmaceutical programs, including lead drug candidate INM-901 for Alzheimer's disease, and answers these questions:

-How soon do you expect to start INM-901 Phase 1 clinical trial enrollment following a successful IND application?
-Will a Phase 1 clinical trial of INM-901 be conducted in healthy volunteers or in patients living with Alzheimer's disease?
-As INM-901 moves into the clinical development phase, do you expect to increase headcount or will this be outsourced?
-While you've had promising preclinical data of INM-901 so far, what gives you the confidence INM-901's preclinical results will translate similarly into human clinical trials?

Watch the presentation and Q&A here: https://www.inmedpharma.com/learn/inmed-presents-at-renmark-financial-virtual-non-deal-roadshow/

$INM Renmark Financial Communications Inc.

InMed’s President and CEO, Eric A. Adams, presents at Renmark Financial’s Virtual Non-Deal Roadshow on February 26, 2026. In the presentation and Q&A, Mr. Adams gives an overview of the company’s pharmaceutical programs, including lead drug candidate INM-901 for Alzheimer’s disease and the u...

03/09/2026

InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

“Looking ahead in 2026, our primary focus is executing activities toward a pre-IND meeting with the FDA in Q3 to discuss the INM-901 program, which we believe will be a key inflection point as we work toward IND submission and initiation of a Phase 1 clinical trial in 2027." ~Eric A. Adams, CEO

Read news release: https://ow.ly/Z1tJ50YrmFe

$INM

03/09/2026

: InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

"We further refined the program’s direction and reinforced our conviction that targeting neuroinflammation is critical to addressing Alzheimer’s disease progression.”

Read news release: https://ow.ly/qe9650YrnaU

$INM

03/09/2026

: InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

-Advancing Alzheimer’s and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling Activities
-Targeting Initiation of Phase 1 Clinical Trial in Alzheimer’s Disease in 2027

Read news release: https://ow.ly/WHSs50Yrmex

$INM

02/26/2026

InMed's CEO, Eric A. Adams, presents at the Renmark Financial Communications Inc. Non-Deal Roadshow.

Eric presents the preclinical studies that demonstrate how INM-901 reduces neuroinflammation associated with Alzheimer's disease. He also talks about the role of CB1 and CB2 receptors in neuroinflammation.

Watch here: https://renmark-drupal.s3.amazonaws.com/vndr/inmed-pharmaceuticals/2026-02-24-14-00-00/index.html

$INM